ArticleAntimicrobial agents and chemotherapy2020
Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.Intensive care medicine · 2022Trial
- Decoding resistance: a comprehensive study on pathogens and antibiotic efficacy in periprosthetic joint infections.Journal of orthopaedic surgery and research · 2026Article
- Simultaneous measurement of piperacillin, tazobactam and meropenem in patient samples using LC-MS/MS to support β-lactam therapeutic drug monitoring.Analytical methods : advancing methods and applications · 2026Article
- Article
- Model-guided dose optimization of cefoperazone-sulbactam and levofloxacin for pneumonia and urinary tract infections in patients with hepatic dysfunction.American journal of translational research · 2026Article
- Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?Chemotherapy · 2026Review
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.Clinical microbiology reviews · 2024Review
- Multistate modeling for survival analysis in critically ill patients treated with meropenem.CPT: pharmacometrics & systems pharmacology · 2024Article
- Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting.Intensive care medicine · 2023Article
- Piperacillin Steady State Concentrations in Target Tissues Relevant for PJI Treatment-A Randomized Porcine Microdialysis Study Comparing Continuous Infusion with Intermittent Short-Term Infusion.Antibiotics (Basel, Switzerland) · 2023Article
- Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.Clinical pharmacokinetics · 2023Article
- Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia?Healthcare (Basel, Switzerland) · 2022Review
- Evaluation and management of platelet transfusion refractoriness.Blood research · 2022Review
- Molecular Investigation of Outer Membrane Channel Genes Among Multidrug Resistance ClinicalReports of biochemistry & molecular biology · 2022Article
- Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of MouseFrontiers in pharmacology · 2022Review
- A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome.Journal of intensive care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.